Meta-analysis finds checkpoint inhibitor combos benefit poor-risk ccRCC patients most

Meta-analysis · Eur Urol · 2026-11-17. Number 1 in the UrologyWatch Top 5 for November 17, 2026.

Pooling individual and aggregate data from four first-line immunotherapy trials in metastatic clear-cell RCC, survival benefit over sunitinib was concentrated in IMDC/CPI2 poor-risk patients (HR 0.51) with minimal benefit in favorable-risk patients (HR 0.98).

Why it matters: Suggests prognostic risk group may help identify which patients derive the most survival benefit from first-line IO combinations.

Limitation: Meta-analysis combining individual and aggregate trial data; favorable-risk subgroup analysis showed no clear benefit.

Source: Eur Urol · PubMed 43039767 · DOI 10.1016/j.eururo.2026.10.014

The full November 17, 2026 edition · Today's urology news

Loading today's edition…